Abstract:
Coated glass pharmaceutical packages are disclosed. According to embodiments, a coated glass pharmaceutical package may include a glass container formed from one of a borosilicate glass composition that meets Type 1 criteria according to USP or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating may be bonded to the exterior surface of the glass container. The low-friction coating may include a polymer. The exterior surface of the glass container with the low-friction coating may have a coefficient of friction of less than or equal to 0.7. The coated glass pharmaceutical package may be thermally stable after depyrogenation in air at a temperature of at least about 260° C. for 30 minutes.
Abstract:
Embodiments of the present disclosure are directed to coated glass articles which reduce glass particle formation caused by glass to glass contact in pharmaceutical glass filling lines.
Abstract:
Disclosed herein are delamination resistant glass pharmaceutical containers which may include a glass body having a Class HGA1 hydrolytic resistance when tested according to the ISO 720:1985 testing standard. The glass body may have an interior surface and an exterior surface. The interior surface of the glass body does not comprise a boron-rich layer when the glass body is in an as-formed condition. A heat-tolerant coating may be bonded to at least a portion of the exterior surface of the glass body. The heat-tolerant coating may have a coefficient of friction of less than about 0.7 and is thermally stable at a temperature of at least 250° C. for 30 minutes.
Abstract:
A pharmaceutical package may include a glass body enclosing an inner volume and having an exterior surface. The glass body may be formed from a borosilicate glass that meets the Type 1 criteria according to USP or an alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A coupling agent layer having a first thickness less than or equal to 100 nm may be disposed on the exterior surface of the glass body. A polymer layer having a second thickness of less than 50 nm may be positioned over the coupling agent layer. The exterior surface of the glass body with the coupling agent layer and the polymer layer may have a coefficient of friction less than or equal to 0.7.
Abstract:
Disclosed herein are delamination resistant glass pharmaceutical containers which may include an aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to ISO 720-1985 testing standard. The glass containers may also have a compressive stress layer with a depth of layer of greater than 25 μm. A surface compressive stress of the glass containers may be greater than or equal to 350 MPa. The delamination resistant glass pharmaceutical containers may be ion exchange strengthened and the ion exchange strengthening may include treating the delamination resistant glass pharmaceutical container in a molten salt bath for a time less than or equal to 5 hours at a temperature less than or equal to 450° C.
Abstract:
Coated pharmaceutical packages are disclosed. In embodiments, a coated pharmaceutical package includes a glass body comprising a first surface. A low-friction coating may be positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. A light transmission through the coated pharmaceutical package may be greater than or equal to about 55% of a light transmission through an uncoated pharmaceutical package for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.
Abstract:
A coated glass pharmaceutical package may include a body formed from a Type 1 Class glass according to ASTM Standard E438-92. The body may have an interior surface and an exterior surface. The body may also have at least a class A2 base resistance or better according to ISO 695, at least a type HGB2 hydrolytic resistance or better according to ISO 719 and a Type 1 chemical durability according to USP . A coating having a thickness of ≦100 microns may be positioned on at least a portion of the exterior surface. The portion of the exterior surface with the coating may have a coefficient of friction that is at least 20% less than an uncoated glass pharmaceutical package and the coefficient of friction does not increase by more than 30% after undergoing a depyrogenation.
Abstract:
One or more aspects relate to an article that includes a glass substrate having a first average strain-to-failure; and a crack mitigating layer disposed on a first major surface of the substrate forming a first interface. The article also includes a film disposed on the crack mitigating layer forming a second interface and having a second average strain-to-failure that is less than the first average strain-to-failure. Further, at least one of the first and second interfaces exhibits a moderate adhesion such that at least a portion of the crack mitigating layer experiences one or more of a cohesive failure and an adhesive failure at the interfaces when the article is strained to a strain level between the first average strain-to-failure and the second average strain-to-failure. In addition, the refractive index of the crack mitigating layer is between or the same as the refractive indices of the substrate and the film.
Abstract:
Low-friction coatings and glass articles with low-friction coatings are disclosed. According to one embodiment, a coated glass article may include a glass body comprising a first surface and a low-friction coating positioned on at least a portion of the first surface of the glass body. The low-friction coating may include a polymer chemical composition. The coated glass article may be thermally stable at a temperature of at least about 260° C. for 30 minutes. A light transmission through the coated glass article may be greater than or equal to about 55% of a light transmission through an uncoated glass article for wavelengths from about 400 nm to about 700 nm. The low-friction coating may have a mass loss of less than about 5% of its mass when heated from a temperature of 150° C. to 350° C. at a ramp rate of about 10° C./minute.
Abstract:
Coated pharmaceutical packages are disclosed. The coated pharmaceutical packages may Include a glass body formed from borosilicate glass that meets Type 1 criteria according to USP or alkali aluminosilicate glass having a Class HGA 1 hydrolytic resistance when tested according to the ISO 720-1985 testing standard. A low-friction coating comprising a polymer may be positioned on a portion of the exterior surface. A coefficient of friction of an abraded area of the portion of the exterior surface with the low-friction coating may be less than 0.7 after exposure to a temperature of 260° C. for 30 minutes and abrasion under a load of at least 10 N and does not have observable damage. A retained strength of the coated glass article in horizontal compression does not decrease by more than 20% after the temperature exposure and the abrasion.